Bli medlem
Bli medlem

Du är här


Change of number of shares and votes in Xbrane

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed share issue of in total 2,817,700 shares. The share issue has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of July 31, 2021 the total number of shares and votes in the Company amounts to 25,039,906. The Company's registered share capital amounts to approximately SEK 5,613,598.


Martin Åmark, CEO
M: +46 76 309 37 77

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilars in its pipeline targeting € 7.9bn in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-07-31 08:00 CEST.


Change of number of shares and votes in Xbrane

Författare MFN